Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45406 | 0.84 | — | — | |
| SCHEMBL29352330 | 0.84 | — | — | |
| SCHEMBL20593017 | 0.82 | ALDH1A1 (0.47) | CES2CES1ACHENFE2L2ALDH1A1 | |
| Methyl Alcohol SCHEMBL27855307 | 0.81 | ACHE (0.56) | CES2CES1ACHENFE2L2ALDH1A1 | |
| Bromide SCHEMBL1357794 | 0.81 | — | — | |
| Lithium SCHEMBL31490346 | 0.81 | — | — | |
| SCHEMBL31435867 | 0.81 | — | — | |
| Fluoride SCHEMBL28523973 | 0.81 | ACHE (0.53) | CES2CES1ACHENFE2L2ALDH1A1 | |
| Hydrogen Sulfide SCHEMBL28163250 | 0.81 | — | — | |
| SCHEMBL9062627 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781562-B1 | PROCESS FOR PREPARING MODULATORS OF P300 AND/OR CBP | CELLCENTRIC LTD (GB) | 2024-11-20 | — | — | EP | disclosed |
| CN-116514722-A | Benzimidazole derivatives as modulators of retinoic acid related orphan receptor gamma (ROR gamma) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3781161-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| CN-112135611-B | Benzimidazole derivatives as modulators of retinoic acid-related orphan receptor gamma (ROR γ) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11453662-B2 | Process for preparing modulators of p300 and/or CBP | CELLCENTRIC LTD (GB) | 2022-09-27 | — | — | US | disclosed |
| US-20210171471-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Uses Thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| US-20210163463-A1 | PROCESS FOR PREPARING MODULATORS OF P300 AND/OR CBP | CELLCENTRIC LTD (GB) | 2021-06-03 | — | — | US | disclosed |
| EP-3781161-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781562-A1 | PROCESS FOR PREPARING MODULATORS OF P300 AND/OR CBP | Cellcentric Ltd (GB) | 2021-02-24 | — | — | EP | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| WO-2005073204-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050143375-A1 | Imidazole derivatives | ROCHE PALO ALTO LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004108701-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248888-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | CES2 1333/4885CES1 1978/4885ACHE 1257/4885 |
| US-20210171471-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Uses Thereof | RORB, RORA, RORC | CES2 4376/4885CES1 983/4885ACHE 3775/4885 |
| US-20210163463-A1 | PROCESS FOR PREPARING MODULATORS OF P300 AND/OR CBP | EP300, CREBBP, KAT7 | CES2 3132/4885CES1 2525/4885ACHE 1657/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | CES2 1286/4885CES1 2902/4885ACHE 815/4885 |
| US-20040248888-A1 | Imidazole derivatives | GRIK5, GRM5, GRIN2B | CES2 1392/4885CES1 1113/4885ACHE 134/4885 |
| US-20050143375-A1 | Imidazole derivatives | GRM5, GRIK5, GRM2 | CES2 2641/4885CES1 2580/4885ACHE 3368/4885 |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | RORB, RORA, RORC | CES2 4390/4885CES1 1003/4885ACHE 3784/4885 |
| US-11453662-B2 | Process for preparing modulators of p300 and/or CBP | EP300, CREBBP, KAT7 | CES2 3132/4885CES1 2525/4885ACHE 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.